Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/20149
Title
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia
Author(s)
Diaz-Beya, Marina | Brunet, S | Nomdedeu, J | Cordeiro, Anna | Tormo, M | Escoda, Lourdes | Ribera, J. M | Arnan, M | Heras, Inmaculada | Gallardo, David | Bargay Lleonart, Joan | Queipo de Llano, Maria Paz | Salamero, O | Marti, J. M | Sampol Mayol, Antonia | Pedro, C | Hoyos, M | Pratcorona, M | Castellano, JJ | Nomdedeu, M | Risueno, RM | Sierra, J | Monzo, M | Navarro, A | Esteve, Jordi
Date issued
2015-10
Citation
Diaz-Beya M, Brunet S, Nomdedeu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct;5:e352.
Language
Inglés
Document type
research article
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
MESH
Disease-Free Survival | Aged | Kaplan-Meier Estimate | Young Adult | Adult | Leukemia, Myeloid, Acute | Humans | Adolescent | Cytogenetic Analysis | Middle Aged | Prognosis | Transcriptome | Male | MicroRNAs | Neoplasm Proteins | Biomarkers, Tumor | Female | Risk Factors | Proportional Hazards Models
DECS
Modelos de Riesgos Proporcionales | Análisis Citogenético | Femenino | Biomarcadores de Tumor | Adolescente | Masculino | Proteínas de Neoplasias | Factores de Riesgo | Humanos | Persona de Mediana Edad | Adulto Joven | Estimación de Kaplan-Meier | Pronóstico | Anciano | Adulto | Leucemia Mieloide Aguda | Supervivencia sin Enfermedad | MicroARNs | Transcriptoma
Online version
DOI
Collections
Full text access